Table 2.

Efficacy of Pretomanid-Containing Regimens

Trial	Regimen	Phenotype	mITT at 6 Months		PP
			Favorable	Unfavorable	Favorable	Unfavorable
NIX-TB^	Pa200 QD, B400 QD x 2 weeks then B200 3x/week, L1200 QD X 30 weeks	XDR (n=71)	63* (90%)	7 (10%)	62 (91%)	6 (9%)
		TI/NR MDR (n=38)	35 (95%)	2(5%)	35 (95%)	2 (5%)
STAND	Pa100 M400 Z1500 X 17 weeks	DS-TB	38 (66.7%)	19 (33.3%)	38 (73.1%)	14 (26.9%)
STAND	Pa200 M400 Z1500 X 17 weeks	DS-TB	46 (75.4%)	15 (24.6%)	46 (80.7%)	11 (19.3%)
STAND	Pa200 M400 Z1500 X 26 weeks	DS-TB	43 (76.8%)	13 (23.2%)	43 (91.5%)	4 (8.5%)
STAND	H75 R150 Z400 E275 X 8 wks; H75 R150 wks 9 to 26	DS-TB	52 (86.7%)	8 (13.3%)	52 (98.1%)	1 (1.9%)
STAND	Pa200 M400 Z1500 X 26 weeks	MDR-TB	10 (90.9%)	1 (9.1%)	10 (100.0%)	0 (0.0%)

Notes: *The following categorical variables had no appreciate impact on mITT: HIV status, linezolid regimen (600 mg BID or 1200 QD), age (above or below median), gender, race (black vs white/other), cavitation, TTP at baseline from MGIT (above or below median). ^NIX-TB- Two exclusions in mITT resulting in total n=107 (non-TB related death in follow up and lost to follow up after end of treatment). Two additional exclusions in PP resulting in total n=105 (one inadequate amount of drug and one withdrawn not for treatment failure).

Abbreviations: mITT, modified intention to treat; PP, per protocol.